DekaBank Deutsche Girozentrale’s Arbutus Biopharma ABUS Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-150,000	Closed	-$331K	–	1484
2023 Q2	$331K	Sell	150,000 -100,000	-40%	-$260K	﹤0.01%	1098
2023 Q1	$734K	Hold	250,000	–	–	﹤0.01%	939
2022 Q4	$565K	Hold	250,000	–	–	﹤0.01%	1008
2022 Q3	$485K	Hold	250,000	–	–	﹤0.01%	1052
2022 Q2	$654K	Hold	250,000	–	–	﹤0.01%	975
2022 Q1	$745K	Hold	250,000	–	–	﹤0.01%	970
2021 Q4	$916K	Hold	250,000	–	–	﹤0.01%	950
2021 Q3	$1.06M	Hold	250,000	–	–	﹤0.01%	890
2021 Q2	$765K	Hold	250,000	–	–	﹤0.01%	973
2021 Q1	$766K	Hold	250,000	–	–	﹤0.01%	953
2020 Q4	$892K	Hold	250,000	–	–	﹤0.01%	895
2020 Q3	$766K	Buy	+250,000	New	+$760K	﹤0.01%	836
2019 Q3	–	Sell	-57,000	Closed	-$129K	–	989
2019 Q2	$129K	Buy	57,000 +22,500	+65%	+$57.6K	﹤0.01%	1059
2019 Q1	$311K	Buy	34,500 +6,000	+21%	+$23K	﹤0.01%	989
2018 Q4	$105K	Sell	28,500 -6,000	-17%	-$29.6K	﹤0.01%	1054
2018 Q3	$311K	Hold	34,500	–	–	﹤0.01%	1011
2018 Q2	$254K	Hold	34,500	–	–	﹤0.01%	1013
2018 Q1	$174K	Buy	+34,500	New	+$183K	﹤0.01%	1007

Other funds holding ABUS

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale's ABUS Position: Q3 2023 in Review

DekaBank Deutsche Girozentrale sold out of Arbutus Biopharma (ABUS) in Q3 2023, closing a stake of 150,000 shares — an estimated $331K sold.

DekaBank Deutsche Girozentrale first reported a position in ABUS in Q1 2018 and held it in 18 quarters. The position peaked at $1.06M in Q3 2021. 99 funds tracked by Wall St. Rank hold ABUS as of Q3 2023.

DekaBank Deutsche Girozentrale reported no remaining Arbutus Biopharma position as of Q3 2023 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 150,000 Arbutus Biopharma shares in Q3 2023, an estimated $331K.
DekaBank Deutsche Girozentrale first reported a position in Arbutus Biopharma in Q1 2018 and held it in 18 quarters.
DekaBank Deutsche Girozentrale's Arbutus Biopharma position peaked at $1.06M in Q3 2021.
99 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2023, filed 13 Nov 2023.